Versartis, Inc. (NASDAQ:VSAR) has been assigned a $14.00 price target by equities research analysts at Cantor Fitzgerald in a note issued to investors on Friday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock.

Several other brokerages have also recently commented on VSAR. ValuEngine cut shares of Versartis from a “hold” rating to a “sell” rating in a research report on Thursday, August 17th. Piper Jaffray Companies cut shares of Versartis from an “overweight” rating to a “neutral” rating and dropped their target price for the company from $26.00 to $4.00 in a research report on Friday, September 22nd. Barclays PLC cut shares of Versartis from an “overweight” rating to an “equal weight” rating and dropped their target price for the company from $28.00 to $4.00 in a research report on Friday, September 22nd. Citigroup Inc. cut shares of Versartis from a “buy” rating to a “neutral” rating and dropped their target price for the company from $23.00 to $3.00 in a research report on Monday, September 25th. Finally, BidaskClub cut shares of Versartis from a “buy” rating to a “hold” rating in a research report on Sunday, July 16th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $7.22.

Shares of Versartis (NASDAQ VSAR) traded down 17.39% during trading on Friday, hitting $1.90. The stock had a trading volume of 3,617,326 shares. The stock’s market capitalization is $67.60 million. The stock’s 50 day moving average is $8.29 and its 200 day moving average is $15.32. Versartis has a 52 week low of $1.90 and a 52 week high of $24.00.

Versartis (NASDAQ:VSAR) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.78). During the same period in the previous year, the business earned ($0.92) earnings per share. On average, equities research analysts expect that Versartis will post ($3.61) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Cantor Fitzgerald Analysts Give Versartis, Inc. (VSAR) a $14.00 Price Target” was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at https://www.americanbankingnews.com/2017/10/28/cantor-fitzgerald-analysts-give-versartis-inc-vsar-a-14-00-price-target.html.

In related news, major shareholder Life Sciences Maste Perceptive sold 2,130,000 shares of the company’s stock in a transaction on Friday, September 22nd. The shares were sold at an average price of $3.29, for a total value of $7,007,700.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 2,132,769 shares of company stock valued at $7,014,761 in the last quarter. Corporate insiders own 10.90% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in VSAR. Russell Investments Group Ltd. increased its position in shares of Versartis by 125.9% in the 1st quarter. Russell Investments Group Ltd. now owns 18,160 shares of the biopharmaceutical company’s stock valued at $387,000 after buying an additional 10,121 shares in the last quarter. Wells Fargo & Company MN increased its position in shares of Versartis by 92.3% in the 1st quarter. Wells Fargo & Company MN now owns 40,779 shares of the biopharmaceutical company’s stock valued at $871,000 after buying an additional 19,568 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Versartis by 21.1% in the 1st quarter. Bank of New York Mellon Corp now owns 164,247 shares of the biopharmaceutical company’s stock valued at $3,506,000 after buying an additional 28,666 shares in the last quarter. American International Group Inc. increased its position in shares of Versartis by 20.7% in the 1st quarter. American International Group Inc. now owns 18,962 shares of the biopharmaceutical company’s stock valued at $405,000 after buying an additional 3,250 shares in the last quarter. Finally, Alliancebernstein L.P. increased its position in shares of Versartis by 246.5% in the 1st quarter. Alliancebernstein L.P. now owns 47,130 shares of the biopharmaceutical company’s stock valued at $1,006,000 after buying an additional 33,530 shares in the last quarter. Institutional investors and hedge funds own 73.61% of the company’s stock.

Versartis Company Profile

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.

Analyst Recommendations for Versartis (NASDAQ:VSAR)

Receive News & Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.